Full-Time

Director Global Clinical Operations

Posted on 12/1/2025

ReCor Medical

ReCor Medical

201-500 employees

Renal denervation system using ultrasound

Compensation Overview

$228k - $250k/yr

Palo Alto, CA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Minimum of Bachelor’s degree in life sciences or related field required; advanced degree (Master’s or above) preferred.
  • Minimum of 10+ years of clinical affairs experience in the medical device, biotech, or pharmaceutical field, with at least 5 years in a leadership role.
  • Proven track record of successfully leading global clinical trials from conception through completion
  • Experience with cardiovascular medical devices; hypertension and/or renal denervation experience preferred
  • Comprehensive understanding of global regulatory requirements (FDA, BSI, etc.) and clinical evidence standards
  • Strong knowledge of clinical research methodologies, biostatistics, and GCP/ISO 14155 standards
  • Excellent leadership abilities with demonstrated success in building and developing high-performing teams
  • Strategic thinker with the ability to translate business objectives into actionable clinical plans
  • Outstanding communication skills with the ability to effectively negotiate matters of significance
  • Experience with global clinical operations, site management, and clinical data management
Responsibilities
  • Participate with senior management to establish strategic clinical plans and objectives aligned with corporate goals
  • Initiate proposed decisions on clinical trial implementation and ensure operational effectiveness across global studies
  • Support the implementation of key business segment strategy into functional clinical plans and guide execution across regions
  • Contribute to development of organizational clinical policies that support regulatory submissions and commercial objectives
  • Ensure clinical budgets and schedules meet corporate requirements and optimize resource utilization
  • Lead the Clinical Affairs department by providing directions to managers and team leaders who oversee daily operations and staff.
  • Lead team(s) to develop new clinical methods and solve complex clinical trial challenges
  • Oversee planning, execution, and completion of clinical trials from protocol development through final clinical study report
  • Establish and implement standardized clinical processes and tools to enhance operational efficiency
  • Manage clinical budget planning, forecasting, and resource allocation to optimize program performance
  • Interact with senior management, executives, and major clinical stakeholders which frequently involves negotiating matters of significance
  • Reconcile multiple stakeholder views to drive clinical study results and organizational objectives
  • Collaborate with Regulatory and Quality Affairs, Medical Affairs, and Scientific Affairs to ensure integrated approaches
  • Partner with Research & Development and new business development to align clinical evidence generation with product development activities
  • Support Marketing and Commercial teams with clinical evidence communication strategies
  • Develop creative solutions when faced with new challenges where there aren't clear precedents or guidelines to follow.
  • Participate in corporate development of methods and techniques for clinical evidence generation
  • Engage with key opinion leaders and clinical investigators to foster strong research partnerships
  • Represent Recor Medical in interactions with regulatory authorities and at scientific conferences
  • Guide development of high-impact clinical publications and presentations
Desired Qualifications
  • Master of Science degree in Life Sciences (or related field) preferred
  • Experience with cardiovascular medical devices; hypertension and/or renal denervation experience preferred (desirable)
  • Advanced degree preferred (already listed in requirements)

ReCor Medical develops the Paradise System, a renal denervation platform that uses non-focused ultrasound to treat hypertension by disrupting renal nerves. It delivers ultrasound energy to the kidneys to ablate nerves, aiming to lower blood pressure in patients whose hypertension does not respond well to traditional medications. It differentiates itself with a non-invasive ultrasound approach and a strong focus on multicenter clinical trials, such as the RADIANCE Global Program, to prove safety and efficacy for regulatory approvals. The goal is to achieve regulatory clearance and broad adoption of the Paradise System in the global healthcare market to provide a durable reduction in blood pressure for patients with resistant hypertension.

Company Size

201-500

Company Stage

Debt Financing

Total Funding

$40M

Headquarters

Palo Alto, California

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • CMS proposed national coverage determination expands reimbursement access for uncontrolled hypertension patients.
  • 2025 AHA/ACC guidelines strengthen clinical support for RDN as treatment option.
  • Veterans partnership with Recon Supply targets 66% uncontrolled hypertension population in VHA.

What critics are saying

  • Medtronic Symplicity RF system captures larger market share with earlier US launch.
  • Post-market surveillance may reveal renal artery stenosis requiring FDA label restrictions.
  • Boston Scientific's CE-marked RDN system blocks European expansion and forces price competition.

What makes ReCor Medical unique

  • Paradise system is first FDA-approved ultrasound renal denervation device for hypertension treatment.
  • HydroCooling technology protects renal artery wall during ultrasound energy delivery procedure.
  • RADIANCE Global Program demonstrated sustained 15.7 mmHg BP reduction at 24 months.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Flexible Work Hours

Company News

PR Newswire
May 16th, 2025
A New Option For Treating High Blood Pressure Is Available To United States Veterans

Ultrasound Renal Denervation, a Proven Treatment for High Blood Pressure, is Available to Veterans Thanks to a Partnership Between Recor Medical and Recon SupplyST. CHARLES, Mo., May 16, 2025 /PRNewswire/ -- Hypertension, or high blood pressure, is known as the "silent killer" because many people do not know they have it and, over time, it can lead to serious health issues. In fact, hypertension increases the risk of heart disease and stroke, two of the leading causes of death in the United States. The 2020 Veterans Health Administration (VHA) guidelines on hypertension define uncontrolled hypertension as a reading above or equal to 130/90 mmHg.1 66% of veterans diagnosed with hypertension are considered uncontrolled by the VHA's guidelines.2Hypertension treatment typically begins with a change in diet, like reducing salt intake, and physical exercise. For some, medication may also be prescribed. However, about one-third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications

PR Newswire
May 17th, 2024
Recor Medical Champions Global Action On World Hypertension Day: Early Intervention And Continued Innovation Crucial In Tackling This Silent Killer Impacting Billions Worldwide

FRANKFURT, GERMANY and PALO ALTO, Calif. , May 17, 2024 /PRNewswire/ -- Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwide. Hypertension is known as the "silent killer" because many people do not know they have it and, over time, it can lead to serious health issues. Hypertension is the number one contributor to the burden of human disease globally, has been associated with a five-year reduction in life expectancy and is a major risk factor for heart disease, stroke, heart attacks and other serious health problems.Bloodpressure Measurement is important with HypertensionMay 17 is World Hypertension Day, a global initiative to highlight the importance of monitoring blood pressure and provide education about this devastating chronic disease. Recor Medical – the pioneer of the Paradise™ Ultrasound Renal Denervation (uRDN) System, a recently FDA-approved medical device-based procedure to treat hypertension – is joining the fight by promoting awareness and encouraging continued innovation and equitable access to early intervention and sustainable solutions for patients suffering from this chronic disease.According to a report from the World Health Organization, the number of adults with hypertension doubled between 1990 and 2019 from 650 million to 1.3 billion. The report also states that only 54 percent of adults with hypertension are diagnosed and only 42 percent receive treatment

PR Newswire
May 17th, 2024
Recor Medical Unterstützt Weltweite Aktionen Zum Welt-Hypertonie-Tag: Frühzeitige Intervention Und Kontinuierliche Innovation Sind Der Schlüssel Zur Bekämpfung Des Stillen Killers, Von Dem Milliarden Menschen Weltweit Betroffen Sind

FRANKFURT, GERMANY and PALO ALTO, Calif., 17. Mai 2024 /PRNewswire/ -- Bluthochdruck, auch Hypertonie genannt, betrifft einen von drei Europäern über 30 Jahre und mehr als eine Milliarde Menschen weltweit. Er wird auch als "stiller Killer" bezeichnet, weil viele Menschen nicht wissen, dass sie daran leiden, und er im Laufe der Zeit zu ernsthaften gesundheitlichen Problemen führen kann. Bluthochdruck ist weltweit der größte Verursacher von Krankheiten und wird mit einer um fünf Jahre verringerten Lebenserwartung in Verbindung gebracht. Er ist ein wichtiger Risikofaktor für Herzkrankheiten, Schlaganfälle, Herzinfarkte und andere schwerwiegende Gesundheitsprobleme.Bloodpressure Measurement is important with HypertensionDer 17. Mai ist der Welt-Hypertonie-Tag, eine weltweite Aktion, die auf die Wichtigkeit der Blutdruckkontrolle hinweist und über diese folgenschwere chronische Krankheit aufklärt

PR Newswire
May 17th, 2024
Recor Medical Soutient Des Actions Mondiales À L'Occasion De La Journée Mondiale De L'Hypertension : L'Intervention Précoce Et L'Innovation Continue Sont Les Clés De La Lutte Contre Ce Tueur Silencieux Qui Affecte Des Milliards De Personnes Dans Le Monde

FRANCFORT, ALLEMAGNE and PALO ALTO, Calif., 17 mai 2024 /PRNewswire/ -- L'hypertension artérielle, ou HTA, touche un Européen sur trois de plus de 30 ans et plus d'un milliard de personnes dans le monde. L'hypertension est appelée le "tueur silencieux" parce que de nombreuses personnes ne savent pas qu'elles en souffrent et qu'elle peut entraîner de graves problèmes de santé au fil du temps. L'hypertension est le premier facteur contribuant à la charge de morbidité mondiale et a été associée à une réduction de cinq ans de l'espérance de vie. Elle constitue un facteur de risque majeur pour les maladies cardiaques, les accidents vasculaires cérébraux, les crises cardiaques et d'autres problèmes de santé graves.Bloodpressure Measurement is important with HypertensionLe 17 mai est la Journée mondiale de l'hypertension, une action mondiale visant à souligner l'importance du contrôle de la tension artérielle et à sensibiliser à cette maladie chronique aux conséquences graves. Recor Medical - le pionnier du système Paradise™ Ultrasound Renal Denervation (uRDN), une technique médicale récemment approuvée par la FDA pour le traitement de l'hypertension artérielle - participe à cet appel en sensibilisant les gens à cette maladie et en encourageant davantage d'innovations et un accès équitable à une intervention précoce et à des solutions durables pour les patients qui souffrent de cette maladie chronique.Selon un rapport de l'Organisation mondiale de la santé, le nombre d'adultes souffrant d'hypertension a doublé entre 1990 et 2019, passant de 650 millions à 1,3 milliard. Le rapport indique également que seuls 54 % des adultes souffrant d'hypertension sont diagnostiqués et que seuls 42 % reçoivent un traitement

MetaMedical Solutions
Nov 13th, 2023
Recor Medical introduces Paradise uRDN system in US

Recor Medical introduces Paradise uRDN system in US.

INACTIVE